Clinical practice guidelines for duodenal cancer 2021
Kenji Nakagawa, Yasuhiro Kodera(Nagoya Medical Center), Tetsuo Ushiku(The University of Tokyo), Souya Nunobe(Japanese Foundation For Cancer Research), Motohiko Kato(Keio University), Mikitaka Iguchi(Wakayama Medical University), Ryota Higuchi(Tokyo Women's Medical University), Shinji Kuroda, Suguru Yamada(Nagoya University), Yukiya Narita(Aichi Cancer Center), Masayuki Sho(Nara Medical University), Tsutomu Fujii(University of Toyama), Kengo Kanetaka(Nagasaki University), Yasuo Ejima(Dokkyo Medical University), Mitsuhiro Fujishiro(Bunkyo University), Takahiro Horimatsu(Kyoto University), Yoshitaka Honma(National Cancer Center Hospital East), Hiroharu Yamashita(The University of Tokyo), Hiroki Yamaue(Wakayama Medical University), Kei Muro(Aichi Cancer Center), Hidetoshi Eguchi(Osaka Gakuin University), Toshio Uraoka, Yuichi Nagakawa(Tokyo Medical University), Yorimasa Yamamoto(The Cancer Institute Hospital), Ken‐ichi Okada(Wakayama Medical University), Toru Aoyama, Shingo Kanaji(Kobe University), Takahiro Akahori(Nara Medical University), Naomi Kakushima(Shizuoka Cancer Center)
Cited by 76
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k